| |
About Us Mission
To protect human lives, to prevent drug adverse reactions, to improve drug efficacy one person and one diagnostic test at a time.
Core Values
Regarding Our Products... Our products will always be designed, redesigned, developed, manufactured, and packaged with utmost focus on quality, reliability, and user friendliness.
To Our Customers... We will place greatest value in customer’s satisfaction. We will deliver only product that is excellent in its quality, is reliable in its performance, and achieves customer satisfaction. We will expedite our responses to our customers’ needs, demands, and questions.
To Our Manufacturing Service Partners... We will conduct ourselves with uncompromising integrity, protect intensely of our partner’s intellectual property and “know-how”, work diligently to accomplish our promised deliverables, and give our best efforts to assist our partners in achieving their goals and objectives.
To Pharmigene Team...We will faithfully collaborate and serve our colleagues in achieving our common objectives. We are committed to a high level of achievement and contribution. We will encourage and support individual innovation and growth. We will have trust and respect for our colleagues. We will reward those who achieve their objectives and contribute to the success of the company.
To Our Shareholders... We will always conduct ourselves with integrity in everything we do. We are fully accountable to achieve our promises. We will work diligently to achieve successes that reward our shareholders.
Company
Pharmigene was founded in 2005 and funded by venture capital firms and individuals. Our goal is to innovate and commercialize diagnostic tests that enable individuals to be better informed about their genomic makeup and to make decisions that better their health. We have licensed exclusive world-wide rights and transferred key know-how from Academia Sinica relating to the genetic markers that are associated with adverse drug reactions caused by several popular drugs. We have obtained ISO 13485/9001 and GMP certifications, and are manufacturing our DNA genetic tests under the most stringent guideline. In developing our DNA genetic tests, we also have validated our tests with clinical studies that involved hundreds and thousands of patients. Today our DNA genetic tests are available world wide. Specifically several of our tests have CE Marking and have obtained IVD clearance from Department of Health in Taiwan.
|
| |
Milestones
| 2005 |
Founded Pharmigene, Inc. |
|
| |
|
|
| 2006 |
Pharmigene licensed exclusive world-wide rights to key technologies from Academia Sinica, Taiwan.
Pharmigene obtained ISO 13485/9001. |
|
| |
|
|
| 2007 |
FDA approved updated labeling to include pharmacogenomics information pertaining to Coumadin® (warfarin). Pharmigene has the rights to the specifically described genetic marker: vitamin K epoxide reductase (VKORC1) through Academia Sinica.
FDA announced updated labeling to include the association of HLA-B*1502 to Tegretol® (carbamazepine) induced Stevens-Johnson syndrome and toxic epidermal necrolysis. |
|
| |
|
|
| 2008 |
Pharmigene received patents “Risk Assessment for Adverse Drug Reactions” issued in USA and Taiwan.
Pharmigene completed manufacturing facility construction.
Pharmigene’s HLA-B*1502 Assessment Test received approval from Department of Health, Taiwan.
Pharmigene’s HLA-B*1502 Assessment Test was selected as the key screening test for a clinical prospective study that involved 27 hospitals and 4500 patients. |
|
| |
|
|
| 2009 |
Pharmigene obtained GMP certification.
Pharmigene received CE Marking for HLA-B*1502 Assessment Test and HLA-B*5801 Assessment Test.
Pharmigene partners with BioPro Pharmaceutical to enter China market.
Pharmigene received patent “Risk Assessment for Adverse Drug Reactions” issued in Singapore. |
|
| |
|
|
| 2010 |
Pharmigene partners with Hai Kang Life Corp. to enter Hong Kong market.
Pharmigene received patent “Risk Assessment for Adverse Drug Reactions” issued in Australia.
Pharmigene’s HLA-B*1502 Assessment Test and Warfarin sensitivity kits received approval from Department of Health, Taiwan.
Pharmigene Secures Patents Related to Genetic-Based Methods to Fight SJS and TENS in the key global regions. <more>
Pharmigene supports Mayo Medical Laboratories in United States. <more> |
|
|
| |
| |
|
|
| |
Y.T. Chen, M.D., Ph.D
Honorary Founder*
Professor, Duke University Medical Center
Director, Academia Sinica, Institute of BioMedical Sciences
|
|
| |
Dr. Y.T. Chen is the scientist who discovered the only life-saving treatment for Pompe Disease and has lead the scientific field in another life-saving discoveries: the screening markers for prevention of Stevens-Johnson syndrome induced by drugs such as carbamazepine and allopurinol, and for prediction of warfarin dosage. Dr. Chen is the Director and Distinguished Research Fellow of Academia Sinica, Institute of BioMedical Sciences. Dr. Chen also has a professorship appointment at Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, and has been the Chief of Division of Medical Genetics from 1994 to 2005. He is also the President of Taiwan Human Genetics Society, and Board of Director of Taiwan Foundation for Rare Disorders. Dr. Chen’s distinguish career also included many honors and awards, and has written over 200 scientific publications. He has received his Ph.D. from Columbia University, New York, and M.D. from National Taiwan University, College of Medicine, Taipei, Taiwan. *Dr. Chen does not hold any position in Pharmigene, and is not involved in Pharmigene's operation. |
|
|
| |
|
|
| |
Luke I. Chen, Ph.D
Chairman and Chief Executive Officer
|
|
| |
Dr. Luke Chen brings years of leadership experience in marketing, sales, business development, product development, manufacturing, licensing and international partnerships. He has a strong track record of achieving sales goals and market share growth, and managing team with diversified technical backgrounds. He is also a member of the Board of Directors of Pharmigene. Prior to his appointment as chief executive officer of Pharmigene, he was the Vice President of sales and marketing for Phalanx Biotech Group (PBG) and Vice President of manufacturing. In his tenure at PBG he had led the company to entered and expanded microarrays, reagents sales and market share in US, Europe, China, Taiwan, and other regions. He has also held management and marketing positions at Agilent Technologies, Hewlett Packard, Incyte, Clontech, & Scimagix. He has received his Ph.D. from University of California, Los Angeles and a BS from University of California, Davis. |
|
| |
|
|
|
| |
|
|---|
| |
United States |
|
Taiwan |
|
| |
 |
|
 |
|
|
|---|
|
|
|
|
